Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26933497 | 1.00 | LIPE (0.44) | LIPESCN9AMRGPRX4HDAC4CHRNB2 | |
| SCHEMBL30152490 | 0.84 | EPHX2 (0.44) | LIPESCN9ARAF1BRAFEPHX2 | |
| SCHEMBL24976933 | 0.84 | EPHX2 (0.44) | LIPESCN9ARAF1BRAFEPHX2 | |
| SCHEMBL23167949 | 0.84 | EPHX2 (0.44) | LIPESCN9ARAF1BRAFEPHX2 | |
| SCHEMBL23167947 | 0.84 | EPHX2 (0.44) | LIPESCN9ARAF1BRAFEPHX2 | |
| SCHEMBL23924384 | 0.83 | GRIN1 (0.48) | CHRNB2CHRNA4EPHX2 | |
| SCHEMBL21492145 | 0.83 | P2RX3 (0.38) | EPHX2 | |
| SCHEMBL23924382 | 0.83 | GRIN1 (0.48) | CHRNB2CHRNA4EPHX2 | |
| SCHEMBL21492239 | 0.82 | CHRNB2 (0.48) | SCN9AMRGPRX4CHRNB2CHRNA4 | |
| SCHEMBL23923870 | 0.81 | GRIN1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313951-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-02-07 | — | — | EP | disclosed |
| US-11845730-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2023-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845730-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | TRPV1, TRPV3, TRPV2 | LIPE 2955/4885SCN9A 1082/4885MRGPRX4 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.